The role of costimulatory molecules in allergic disease and asthma

International Archives of Allergy and Immunology

Volumn 151, Issue 3, 2010, Pages 179-189

  Lombardi, Vincent ^a   Singh, Abinav K ^a   Akbari, Omid ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Allergy; Asthma; Costimulatory molecules

Indexed keywords

B7 ANTIGEN; CD134 ANTIGEN; CD137 ANTIGEN; CD2 ANTIGEN; CD27 ANTIGEN; CD28 ANTIGEN; CD30 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; FAS ANTIGEN; TUMOR NECROSIS FACTOR RECEPTOR;

ALLERGIC DISEASE; ASTHMA; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, CD86; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; ASTHMA; HUMANS; HYPERSENSITIVITY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; RECEPTORS, IMMUNOLOGIC; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 70349421440     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000242355     Document Type: Review

References (101)

1. Masoli M, Fabian D, Holt S, Beasley R: The global burden of asthma: executive summary of the GINA dissemination committee report. Allergy 2004; 59: 469-478.
2. Bousquet J, Khaltaev N: Global Surveillance, Prevention and Control of Chronic Respiratory Diseases. Geneva, World Health Organization, 2007, pp 15-20.
3. Tse K, Horner AA: Allergen tolerance versus the allergic march: the hygiene hypothesis revisited. Curr Allergy Asthma Rep 2008; 8: 475-483.
4. Kim H, Bernstein JA: Air pollution and allergic disease. Curr Allergy Asthma Rep 2009; 9: 128-133.
5. Meiler F, Zimmermann M, Blaser K, Akdis CA, Akdis M: T cell subsets in the pathogenesis of human asthma. Curr Allergy Asthma Rep 2006; 6: 91-96.
6. Lafferty KJ, Cooley MA, Woolnough J, Walker KZ: Thyroid allograft immunogenicity is reduced after a period in organ culture. Science 1975; 188: 259-261.
7. Greenwald RJ, Freeman GJ, Sharpe AH: The B7 family revisited. Annu Rev Immunol 2005; 23: 515-548.
8. Croft M: Co-stimulatory members of the TNFR family: keys to effective T cell immunity? Nat Rev Immunol 2003; 3: 609-620.
9. Burr JS, Kimzey SL, Randolph DR, Green JM: CD28 and CTLA4 coordinately regulate airway inflammatory cell recruitment and T helper cell differentiation after inhaled allergen. Am J Respir Cell Mol Biol 2001; 24: 563-568.
10. Hofer MF, Jirapongsananuruk O, Trumble AE, Leung DY: Upregulation of B7.2, but not B7.1, on B cells from patients with allergic asthma. J Allergy Clin Immunol 1998; 101: 96-102.
11. Agea E, Forenza N, Piattoni S, Russano A, Monaco A, Flenghi L, Bistoni O, Gillies DA, Azuma M, Bertotto A, Spinozzi F: Expression of B7 co-stimulatory molecules and CD1a antigen by alveolar macrophages in allergic bronchial asthma. Clin Exp Allergy 1998; 28: 1359-1367.
12. Burastero SE, Magnani Z, Confetti C, Abbruzzese L, Oddera S, Balbo P, Rossi GA, Crimi E: Increased expression of the CD80 accessory molecule by alveolar macrophages in asthmatic subjects and its functional involvement in allergen presentation to autologous Th2 lymphocytes. J Allergy Clin Immunol 1999; 103: 1136-1142.
13. Jeannin P, Magistrelli G, Aubry JP, Caron G, Gauchat JF, Renno T, Herbault N, Goetsch L, Blaecke A, Dietrich PY, Bonnefoy JY, Delneste Y: Soluble CD86 is a costimulatory molecule for human T lymphocytes. Immunity 2000; 13: 303-312.
14. Shi HZ, Xie ZF, Deng JM, Chen YQ, Xiao CQ: Soluble CD86 protein in serum samples of patients with asthma. Thorax 2004; 59: 870-875.
15. Deng JM, Shi HZ, Qin XJ, Xie ZF, Huang CP, Zhong XN: Effects of allergen inhalation and oral glucocorticoid on concentrations of serum-soluble CD86 in allergic asthmatics. Clin Immunol 2005; 115: 178-183.
16. Ritprajak P, Hashiguchi M, Azuma M: Topical application of cream-emulsified CD86 siRNA ameliorates allergic skin disease by targeting cutaneous dendritic cells. Mol Ther 2008; 16: 1323-1330.
17. Akbari O, DeKruyff RH, Umetsu DT: Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol 2001; 2: 725-731.
18. Hutloff A, Dittrich AM, Beier KC, Eljaschewitsch B, Kraft R, Anagnostopoulos I, Kroczek RA: ICOS is an inducible T cell costimulator structurally and functionally related to CD28. Nature 1999; 397: 263-266.
19. Akbari O, Stock P, Meyer EH, Freeman GJ, Sharpe AH, Umetsu DT, DeKruyff RH: ICOS/ICOSL interaction is required for CD4+ invariant NKT cell function and homeostatic survival. J Immunol 2008; 180: 5448-5456.
20. McAdam AJ, Chang TT, Lumelsky AE, Greenfield EA, Boussiotis VA, Duke-Cohan JS, Chernova T, Malenkovich N, Jabs C, Kuchroo VK, Ling V, Collins M, Sharpe AH, Freeman GJ: Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differentiation of CD4+ T cells. J Immunol 2000; 165: 5035-5040.
21. Gonzalo JA, Tian J, Delaney T, Corcoran J, Rottman JB, Lora J, Al-garawi A, Kroczek R, Gutierrez-Ramos JC, Coyle AJ: ICOS is critical for T helper cell-mediated lung mucosal inflammatory responses. Nat Immunol 2001; 2: 597-604.
22. Tesciuba AG, Subudhi S, Rother RP, Faas SJ, Frantz AM, Elliot D, Weinstock J, Matis LA, Bluestone JA, Sperling AI: Inducible costimulator regulates Th2-mediated inflammation, but not Th2 differentiation, in a model of allergic airway disease. J Immunol 2001; 167: 1996-2003.
23. Tesciuba AG, Shilling RA, Agarwal MD, Bandukwala HS, Clay BS, Moore TV, Weinstock JV, Welcher AA, Sperling AI: ICOS costimulation expands Th2 immunity by augmenting migration of lymphocytes to draining lymph nodes. J Immunol 2008; 181: 1019-1024.
24. Beier KC, Hutloff A, Lohning M, Kallinich T, Kroczek RA, Hamelmann E: Inducible costimulator-positive T cells are required for allergen-induced local B-cell infiltration and antigen-specific IgE production in lung tissue. J Allergy Clin Immunol 2004; 114: 775-782.
25. Kobayashi N, Nagumo H, Agematsu K: IL-10 enhances B-cell IgE synthesis by promoting differentiation into plasma cells, a process that is inhibited by CD27/CD70 interaction. Clin Exp Immunol 2002; 129: 446-452.
26. Dong C, Juedes AE, Temann UA, Shresta S, Allison JP, Ruddle NH, Flavell RA: ICOS costimulatory receptor is essential for T cell activation and function. Nature 2001; 409: 97-101.
27. Lohning M, Hutloff A, Kallinich T, Mages HW, Bonhagen K, Radbruch A, Hamelmann E, Kroczek RA: Expression of ICOS in vivo defines CD4+ effector T cells with high inflammatory potential and a strong bias for secretion of interleukin 10. J Exp Med 2003; 197: 181-193.
28. Akbari O, Freeman GJ, Meyer EH, Greenfield EA, Chang TT, Sharpe AH, Berry G, DeKruyff RH, Umetsu DT: Antigen-specific regulatory T cells develop via the ICOSICOS-ligand pathway and inhibit allergeninduced airway hyperreactivity. Nat Med 2002; 8: 1024-1032.
29. Tuettenberg A, Huter E, Hubo M, Horn J, Knop J, Grimbacher B, Kroczek RA, Stoll S, Jonuleit H: The role of ICOS in directing T cell responses: ICOS-dependent induction of T cell anergy by tolerogenic dendritic cells. J Immunol 2009; 182: 3349-3356.
30. Taylor A, Akdis M, Joss A, Akkoc T, Wenig R, Colonna M, Daigle I, Flory E, Blaser K, Akdis CA: IL-10 inhibits CD28 and ICOS costimulations of T cells via Src homology 2 domain-containing protein tyrosine phosphatase 1. J Allergy Clin Immunol 2007; 120: 76-83.
31. Bauquet AT, Jin H, Paterson AM, Mitsdoerffer M, Ho IC, Sharpe AH, Kuchroo VK: The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and Th-17 cells. Nat Immunol 2009; 10: 167-175.
32. Kaneda H, Takeda K, Ota T, Kaduka Y, Akiba H, Ikarashi Y, Wakasugi H, Kronenberg M, Kinoshita K, Yagita H, Okumura K: ICOS costimulates invariant NKT cell activation. Biochem Biophys Res Commun 2005; 327: 201-207.
33. Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, Mak TW, Sakaguchi S: Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000; 192: 303-310.
34. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH: Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995; 3: 541-547.
35. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H, Mak TW: Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995; 270: 985-988.
36. Read S, Malmstrom V, Powrie F: Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2000; 192: 295-302.
37. Howard TD, Postma DS, Hawkins GA, Koppelman GH, Zheng SL, Wysong AK, Xu J, Meyers DA, Bleecker ER: Fine mapping of an IgE-controlling gene on chromosome 2q: analysis of CTLA4 and CD28. J Allergy Clin Immunol 2002; 110: 743-751.
38. Lee SY, Lee YH, Shin C, Shim JJ, Kang KH, Yoo SH, In KH: Association of asthma severity and bronchial hyperresponsiveness with a polymorphism in the cytotoxic T lymphocyte antigen-4 gene. Chest 2002; 122: 171-176.
39. Hizawa N, Yamaguchi E, Jinushi E, Konno S, Kawakami Y, Nishimura M: Increased total serum IgE levels in patients with asthma and promoter polymorphisms at CTLA4 and FCER1B. J Allergy Clin Immunol 2001; 108: 74-79.
40. Meiler F, Zumkehr J, Klunker S, Ruckert B, Akdis CA, Akdis M: In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J Exp Med 2008; 205: 2887-2898.
41. Van Overtvelt L, Wambre E, Maillere B, von Hofe E, Louise A, Balazuc AM, Bohle B, Ebo D, Leboulaire C, Garcia G, Moingeon P: Assessment of Bet v 1-specific CD4+ T cell responses in allergic and nonallergic individuals using MHC class II peptide tetramers. J Immunol 2008; 180: 4514-4522.
42. Linhart B, Bigenzahn S, Hartl A, Lupinek C, Thalhamer J, Valenta R, Wekerle T: Costimulation blockade inhibits allergic sensitization but does not affect established allergy in a murine model of grass pollen allergy. J Immunol 2007; 178: 3924-3931.
43. Ishida Y, Agata Y, Shibahara K, Honjo T: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992; 11: 3887-3895.
44. Nishimura H, Nose M, Hiai H, Minato N, Honjo T: Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999; 11: 141-151.
45. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, Honjo T: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192: 1027-1034.
46. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, Greenfield EA, Bourque K, Boussiotis VA, Carter LL, Carreno BM, Malenkovich N, Nishimura H, Okazaki T, Honjo T, Sharpe AH, Freeman GJ: PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2: 261-268.
47. Tseng SY, Otsuji M, Gorski K, Huang X, Slansky JE, Pai SI, Shalabi A, Shin T, Pardoll DM, Tsuchiya H: B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 2001; 193: 839-846.
48. Matsumoto K, Fukuyama S, Eguchi-Tsuda M, Nakano T, Matsumoto T, Matsumura M, Moriwaki A, Kan-o K, Wada Y, Yagita H, Shin T, Pardoll DM, Patcharee R, Azuma M, Nakanishi Y, Inoue H: B7-DC induced by IL-13 works as a feedback regulator in the effector phase of allergic asthma. Biochem Biophys Res Commun 2008; 365: 170-175.
49. Matsumoto K, Inoue H, Nakano T, Tsuda M, Yoshiura Y, Fukuyama S, Tsushima F, Hoshino T, Aizawa H, Akiba H, Pardoll D, Hara N, Yagita H, Azuma M, Nakanishi Y: B7-DC regulates asthmatic response by an IFNgamma-dependent mechanism. J Immunol 2004; 172: 2530-2541.
50. Radhakrishnan S, Iijima K, Kobayashi T, Rodriguez M, Kita H, Pease LR: Blockade of allergic airway inflammation following systemic treatment with a B7-dendritic cell (PD-L2) cross-linking human antibody. J Immunol 2004; 173: 1360-1365.
51. Oflazoglu E, Swart DA, Anders-Bartholo P, Jessup HK, Norment AM, Lawrence WA, Brasel K, Tocker JE, Horan T, Welcher AA, Fitzpatrick DR: Paradoxical role of programmed death-1 ligand 2 in Th2 immune responses in vitro and in a mouse asthma model in vivo. Eur J Immunol 2004; 34: 3326-3336.
52. Fukushima A, Yamaguchi T, Azuma M, Yagita H, Ueno H: Involvement of programmed death-ligand 2 (PD-L2) in the development of experimental allergic conjunctivitis in mice. Br J Ophthalmol 2006; 90: 1040-1045.
53. Gajewska BU, Tafuri A, Swirski FK, Walker T, Johnson JR, Shea T, Shahinian A, Goncharova S, Mak TW, Stampfli MR, Jordana M: B7RP-1 is not required for the generation of Th2 responses in a model of allergic airway inflammation but is essential for the induction of inhalation tolerance. J Immunol 2005; 174: 3000-3005.
54. Kim HK, Guan H, Zu G, Li H, Wu L, Feng X, Elmets C, Fu Y, Xu H: High-level expression of B7-H1 molecules by dendritic cells suppresses the function of activated T cells and desensitizes allergen-primed animals. J Leukoc Biol 2006; 79: 686-695.
55. Tsushima F, Iwai H, Otsuki N, Abe M, Hirose S, Yamazaki T, Akiba H, Yagita H, Takahashi Y, Omura K, Okumura K, Azuma M: Preferential contribution of B7-H1 to programmed death-1-mediated regulation of hapten-specific allergic inflammatory responses. Eur J Immunol 2003; 33: 2773-2782.
56. Piconi S, Trabattoni D, Saresella M, Iemoli E, Schenal M, Fusi A, Borelli M, Chen L, Mascheri A, Clerici M: Effects of specific immunotherapy on the B7 family of costimulatory molecules in allergic inflammation. J Immunol 2007; 178: 1931-1937.
57. Allam JP, Novak N, Fuchs C, Asen S, Berge S, Appel T, Geiger E, Kochan JP, Bieber T: Characterization of dendritic cells from human oral mucosa: a new Langerhans' cell type with high constitutive FcepsilonRI expression. J Allergy Clin Immunol 2003; 112: 141-148.
58. Allam JP, Peng WM, Appel T, Wenghoefer M, Niederhagen B, Bieber T, Berge S, Novak N: Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells. J Allergy Clin Immunol 2008; 121: 368-374.
59. Nagashima O, Harada N, Usui Y, Yamazaki T, Yagita H, Okumura K, Takahashi K, Akiba H: B7-H3 contributes to the development of pathogenic Th2 cells in a murine model of asthma. J Immunol 2008; 181: 4062-4071.
60. Fukushima A, Sumi T, Fukuda K, Kumagai N, Nishida T, Yamazaki T, Akiba H, Okumura K, Yagita H, Ueno H: B7-H3 regulates the development of experimental allergic conjunctivitis in mice. Immunol Lett 2007; 113: 52-57.
61. Chen AI, McAdam AJ, Buhlmann JE, Scott S, Lupher ML Jr, Greenfield EA, Baum PR, Fanslow WC, Calderhead DM, Freeman GJ, Sharpe AH: OX40-ligand has a critical costimulatory role in dendritic cell: T cell interactions. Immunity 1999; 11: 689-698.
62. Ohshima Y, Yang LP, Uchiyama T, Tanaka Y, Baum P, Sergerie M, Hermann P, Delespesse G: OX40 costimulation enhances interleukin-4 (IL-4) expression at priming and promotes the differentiation of naive human CD4(+) T cells into high IL-4-producing effectors. Blood 1998; 92: 3338-3345.
63. Ito T, Wang YH, Duramad O, Hori T, Delespesse GJ, Watanabe N, Qin FX, Yao Z, Cao W, Liu YJ: TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J Exp Med 2005; 202: 1213-1223.
64. Hoshino A, Tanaka Y, Akiba H, Asakura Y, Mita Y, Sakurai T, Takaoka A, Nakaike S, Ishii N, Sugamura K, Yagita H, Okumura K: Critical role for OX40 ligand in the development of pathogenic Th2 cells in a murine model of asthma. Eur J Immunol 2003; 33: 861-869.
65. Salek-Ardakani S, Song J, Halteman BS, Jember AG, Akiba H, Yagita H, Croft M: OX40 (CD134) controls memory T helper 2 cells that drive lung inflammation. J Exp Med 2003; 198: 315-324.
66. Jember AG, Zuberi R, Liu FT, Croft M: Development of allergic inflammation in a murine model of asthma is dependent on the costimulatory receptor OX40. J Exp Med 2001; 193: 387-392.
67. Duan W, So T, Croft M: Antagonism of airway tolerance by endotoxin/lipopolysaccharide through promoting OX40L and suppressing antigen-specific Foxp3+ T regulatory cells. J Immunol 2008; 181: 8650-8659.
68. So T, Salek-Ardakani S, Nakano H, Ware CF, Croft M: TNF receptor-associated factor 5 limits the induction of Th2 immune responses. J Immunol 2004; 172: 4292-4297.
69. Vu MD, Xiao X, Gao W, Degauque N, Chen M, Kroemer A, Killeen N, Ishii N, Chang Li X: OX40 costimulation turns off Foxp3+ Tregs. Blood 2007; 110: 2501-2510.
70. Gri G, Piconese S, Frossi B, Manfroi V, Merluzzi S, Tripodo C, Viola A, Odom S, Rivera J, Colombo MP, Pucillo CE: CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity 2008; 29: 771-781.
71. Diana J, Griseri T, Lagaye S, Beaudoin L, Autrusseau E, Gautron AS, Tomkiewicz C, Herbelin A, Barouki R, von Herrath M, Dalod M, Lehuen A: NKT cell-plasmacytoid dendritic cell cooperation via OX40 controls viral infection in a tissue-specific manner. Immunity 2009; 30: 289-299.
72. Zaini J, Andarini S, Tahara M, Saijo Y, Ishii N, Kawakami K, Taniguchi M, Sugamura K, Nukiwa T, Kikuchi T: OX40 ligand expressed by DCs costimulates NKT and CD4+ Th cell antitumor immunity in mice. J Clin Invest 2007; 117: 3330-3338.
73. Heshmat NM, El-Hadidi ES: Soluble CD30 serum levels in atopic dermatitis and bronchial asthma and its relationship with disease severity in pediatric age. Pediatr Allergy Immunol 2006; 17: 297-303.
74. Oflazoglu E, Simpson EL, Takiguchi R, Grewal IS, Hanifin JM, Gerber HP: CD30 expression on CD1a+ and CD8+ cells in atopic dermatitis and correlation with disease severity. Eur J Dermatol 2008; 18: 41-49.
75. Rojas-Ramos E, Garfias Y, Jimenez-Martinez Mdel C, Martinez-Jimenez N, Zenteno E, Gorocica P, Lascurain R: Increased expression of CD30 and CD57 molecules on CD4(+) T cells from children with atopic asthma: a preliminary report. Allergy Asthma Proc 2007; 28: 659-666.
76. Foschi FG, Emiliani F, Savini S, Quercia O, Stefanini GF: CD30 serum levels and response to hymenoptera venom immunotherapy. J Investig Allergol Clin Immunol 2008; 18: 279-283.
77. Croft M: The role of TNF superfamily members in T cell function and diseases. Nat Rev Immunol 2009; 9: 271-285.
78. Heinisch IV, Bizer C, Volgger W, Simon HU: Functional CD137 receptors are expressed by eosinophils from patients with IgE-mediated allergic responses but not by eosinophils from patients with non-IgE-mediated eosinophilic disorders. J Allergy Clin Immunol 2001; 108: 21-28.
79. Cho YS, Kwon B, Lee TH, Kim TB, Moon KA, La S, Lee J, Lee SD, Oh YM, Moon HB: 4-1BB stimulation inhibits allergen-specific immunoglobulin E production and airway hyper-reactivity but partially suppresses bronchial eosinophilic inflammation in a mouse asthma model. Clin Exp Allergy 2006; 36: 377-385.
80. Nishimoto H, Lee SW, Hong H, Potter KG, Maeda-Yamamoto M, Kinoshita T, Kawakami Y, Mittler RS, Kwon BS, Ware CF, Croft M, Kawakami T: Costimulation of mast cells by 4-1BB, a member of the tumor necrosis factor receptor superfamily, with the highaffinity IgE receptor. Blood 2005; 106: 4241-4248.
81. Polte T, Foell J, Werner C, Hoymann HG, Braun A, Burdach S, Mittler RS, Hansen G: CD137-mediated immunotherapy for allergic asthma. J Clin Invest 2006; 116: 1025-1036.
82. Polte T, Jagemann A, Foell J, Mittler RS, Hansen G: CD137 ligand prevents the development of T helper type 2 cell-mediated allergic asthma by interferon-gamma-producing CD8+ T cells. Clin Exp Allergy 2007; 37: 1374-1385.
83. Fukushima A, Yamaguchi T, Ishida W, Fukata K, Mittler RS, Yagita H, Ueno H: Engagement of 4-1BB inhibits the development of experimental allergic conjunctivitis in mice. J Immunol 2005; 175: 4897-4903.
84. Tsuyuki S, Bertrand C, Erard F, Trifilieff A, Tsuyuki J, Wesp M, Anderson GP, Coyle AJ: Activation of the Fas receptor on lung eosinophils leads to apoptosis and the resolution of eosinophilic inflammation of the airways. J Clin Invest 1995; 96: 2924-2931.
85. Duez C, Tomkinson A, Shultz LD, Bratton DL, Gelfand EW: Fas deficiency delays the resolution of airway hyperresponsiveness after allergen sensitization and challenge. J Allergy Clin Immunol 2001; 108: 547-556.
86. Tong J, Bandulwala HS, Clay BS, Anders RA, Shilling RA, Balachandran DD, Chen B, Weinstock JV, Solway J, Hamann KJ, Sperling AI: Fas-positive T cells regulate the resolution of airway inflammation in a murine model of asthma. J Exp Med 2006; 203: 1173-1184.
87. Chuang YH, Suen JL, Chiang BL: Fas-ligandexpressing adenovirus- transfected dendritic cells decrease allergen-specific T cells and airway inflammation in a murine model of asthma. J Mol Med 2006; 84: 595-603.
88. Uller L, Rydell-Tormanen K, Persson CG, Erjefalt JS: Anti-Fas mAB induced apoptosis and cytolysis of airway tissue eosinophils aggravates rather than resolves established inflammation. Respir Res 2005; 6: 90.
89. Goodwin RG, Alderson MR, Smith CA, Armitage RJ, VandenBos T, Jerzy R, Tough TW, Schoenborn MA, Davis-Smith T, Hennen K, et al: Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor. Cell 1993; 73: 447-456.
90. Agematsu K, Kobata T, Sugita K, Hirose T, Schlossman SF, Morimoto C: Direct cellular communications between CD45RO and CD45RA T cell subsets via CD27/CD70. J Immunol 1995; 154: 3627-3635.
91. Sumi T, Ishida W, Ojima A, Kajisako M, Sakanishi T, Yagita H, Fukushima A: CD27 and CD70 do not play a critical role in the development of experimental allergic conjunctivitis in mice. Immunol Lett 2008; 119: 91-96.
92. Grewal IS, Flavell RA: CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998; 16: 111-135.
93. Poulsen LK, Hummelshoj L: Triggers of IgE class switching and allergy development. Ann Med 2007; 39: 440-456.
94. Lei XF, Ohkawara Y, Stampfli MR, Mastruzzo C, Marr RA, Snider D, Xing Z, Jordana M: Disruption of antigen-induced inflammatory responses in CD40 ligand knockout mice. J Clin Invest 1998; 101: 1342-1353.
95. Wiley JA, Geha R, Harmsen AG: Exogenous CD40 ligand induces a pulmonary inflammation response. J Immunol 1997; 158: 2932-2938.
96. Suzuki M, Zheng X, Zhang X, Ichim TE, Sun H, Kubo N, Beduhn M, Shunnar A, Garcia B, Min WP: Inhibition of allergic responses by CD40 gene silencing. Allergy 2009; 64: 387-397.
97. Moingeon P, Chang HC, Sayre PH, Clayton LK, Alcover A, Gardner P, Reinherz EL: The structural biology of CD2. Immunol Rev 1989; 111: 111-144.
98. Wingren AG, Parra E, Varga M, Kalland T, Sjogren HO, Hedlund G, Dohlsten M: T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles. Crit Rev Immunol 1995; 15: 235-253.
99. Biancone L, Andres G, Ahn H, Lim A, Dai C, Noelle R, Yagita H, De Martino C, Stamenkovic I: Distinct regulatory roles of lymphocyte costimulatory pathways on T helper type-2 mediated autoimmune disease. J Exp Med 1996; 183: 1473-1481.
100. Taylor A, Verhagen J, Akkoc T, Wenig R, Flory E, Blaser K, Akdis M, Akdis CA: IL-10 suppresses CD2-mediated T cell activation via SHP-1. Mol Immunol 2009; 46: 622-629.
101. Cheng YX, Foster B, Holland SM, Klion AD, Nutman TB, Casale TB, Metcalfe DD, Prussin C: CD2 identifies a monocyte subpopulation with immunoglobulin E-dependent, high-level expression of Fc epsilon RI. Clin Exp Allergy 2006; 36: 1436-1445.